187 related articles for article (PubMed ID: 24215622)
1. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
Roddick LA; Bhakta V; Sheffield WP
BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
[TBL] [Abstract][Full Text] [Related]
2. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
Sutherland JS; Bhakta V; Filion ML; Sheffield WP
Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
[TBL] [Abstract][Full Text] [Related]
3. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
[TBL] [Abstract][Full Text] [Related]
4. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.
Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S
Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677
[TBL] [Abstract][Full Text] [Related]
5. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
[TBL] [Abstract][Full Text] [Related]
6. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
7. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity.
Bhakta V; Gierczak RF; Sheffield WP
J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600
[TBL] [Abstract][Full Text] [Related]
8. The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
Sheffield WP; Bhakta V
Biochem Biophys Res Commun; 2016 Feb; 470(3):710-713. PubMed ID: 26797521
[TBL] [Abstract][Full Text] [Related]
9. Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.
Scott BM; Matochko WL; Gierczak RF; Bhakta V; Derda R; Sheffield WP
PLoS One; 2014; 9(1):e84491. PubMed ID: 24427287
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity.
Gierczak RF; Bhakta V; Xie M; Sheffield WP
J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
Gierczak RF; Pepler L; Bhagirath V; Liaw PC; Sheffield WP
Thromb Res; 2014 Nov; 134(5):1142-9. PubMed ID: 25242242
[TBL] [Abstract][Full Text] [Related]
12. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
Myles T; Church FC; Whinna HC; Monard D; Stone SR
J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
[TBL] [Abstract][Full Text] [Related]
13. Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells.
Gierczak RF; Sutherland JS; Bhakta V; Toltl LJ; Liaw PC; Sheffield WP
J Thromb Haemost; 2011 Dec; 9(12):2424-35. PubMed ID: 21972922
[TBL] [Abstract][Full Text] [Related]
14. Conformational changes in thrombin when complexed by serpins.
Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 2001 Nov; 276(48):44828-34. PubMed ID: 11584020
[TBL] [Abstract][Full Text] [Related]
15. Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes.
Maekawa H; Tollefsen DM
J Biol Chem; 1996 Aug; 271(31):18604-9. PubMed ID: 8702511
[TBL] [Abstract][Full Text] [Related]
16. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II.
Hortin GL; Tollefsen DM; Benutto BM
J Biol Chem; 1989 Aug; 264(24):13979-82. PubMed ID: 2760054
[TBL] [Abstract][Full Text] [Related]
18. Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.
Sarilla S; Habib SY; Kravtsov DV; Matafonov A; Gailani D; Verhamme IM
J Biol Chem; 2010 Mar; 285(11):8278-89. PubMed ID: 20053992
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Van Deerlin VM; Tollefsen DM
J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel recombinant serpin with potential antithrombotic properties.
Hopkins PC; Crowther DC; Carrell RW; Stone SR
J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
